Interview https://www.benzinga.com/views/taxonomy/term/125566 en 'Like A 1950's Black-And-White Fuzzy TV': How One Fintech Startup Completely Changed The Way We Think About Risk https://www.benzinga.com/personal-finance/financial-advisors/18/07/12046222/like-a-1950s-black-and-white-fuzzy-tv-how-one-fin <p><em>How much should I risk?</em></p> <p>There is perhaps no five-word combination in the history of investing that has confounded investors as much as this one.</p> <p>Finding the answer to that question and others that surround it&mdash;like <em>What is my risk tolerance? </em>and <em>When should I sell?</em>&mdash;is partly how the financial advisory industry was built. After all, it&rsquo;s easier to let a professional handle the tough questions.</p> <p>And handle it they did. The number of financial advisors in the U.S. reached 325,000 at its peak in 2008, but as anyone in the industry knows that number has <a href="https://www.reuters.com/article/wealth-cerulli-advisor-headcount/number-of-u-s-financial-advisers-fell-for-fifth-straight-year-report-idUSL1N0VL23920150211">dropped substantially </a>in recent years&mdash;down to about <a href="https://www.bls.gov/oes/current/oes132052.htm#nat">200,000 in 2017</a>&mdash;as the explosion of robo-advisors and ETFs have made self-directed investing easier than ever.</p> <p>So, while the fundamental question still remains, the trouble is compounded by a new dimension: <em>Who, or what, should I trust to know how much I should risk?</em></p> <p>The answer to that question is what a pair of finance veterans set out to find.</p> <h3>Going Against Human Nature</h3> <p>In 2010 Aaron Klein was the director of product for OptionsXpress where, in his own words, he &ldquo;saw firsthand how poorly average investors think about risk.&rdquo;</p> <p>His friend Michael McDaniel was a financial advisor, and the two got to talking.</p> <p>&ldquo;I remember saying to him &lsquo;I think it&rsquo;s crazy how the average investor talks about the concept of risk.&rsquo;&rdquo; Klein said. &ldquo;And he says &lsquo;If you think that&rsquo;s crazy, you should see how many of their financial advisors think about it.&rsquo;&rdquo;</p> <p>When it comes to assessing risk, financial advisor conventional wisdom starts with age. If you&rsquo;re young you&rsquo;re probably aggressive, and if you&rsquo;re old you&rsquo;re probably conservative. Or so the logic goes.</p> <p>&ldquo;Then we ask a few nonsensical questions like ...</p><p><a href=https://www.benzinga.com/personal-finance/financial-advisors/18/07/12046222/like-a-1950s-black-and-white-fuzzy-tv-how-one-fin alt=&#039;Like A 1950&#039;s Black-And-White Fuzzy TV&#039;: How One Fintech Startup Completely Changed The Way We Think About Risk>Full story available on Benzinga.com</a></p> Financial Advisors Fintech Riskalyze Movers & Shakers Top Stories Success Stories Startups Personal Finance Interview General Financial Advisors Fintech Movers & Shakers Top Stories Success Stories Startups Personal Finance Interview General Benzinga Thu, 19 Jul 2018 17:58:46 +0000 Spencer Israel 12046222 at https://www.benzinga.com Financial Advisers Need To Be More Engaging, And This Fintech Company Wants To Help https://www.benzinga.com/personal-finance/financial-advisors/18/07/12046075/financial-advisers-need-to-be-more-engaging-and-t <p>In 2018, every consumer-facing platform is concerned with the same thing: user engagement.</p> <p>From media, where the head of HBO opened up about the need to focus on &ldquo;<a href="https://www.nytimes.com/2018/07/08/business/media/hbo-att-merger.html">hours in the day</a>,&rdquo; to Wall Street, where <a href="https://www.bloomberg.com/news/articles/2018-07-09/twilio-sending-bullish-signals-with-customer-engagement-software">companies are rewarded</a> for their commitment to customer engagement.</p> <p>Unsurprisingly, this trend has spread to financial advisement, an industry not typically known for its transparency.</p> <p>But that&rsquo;s changing. In part due to companies like InvestCloud, a digital platform for money managers. InvestCloud&rsquo;s mandate, according to Chief Marketing Officer Mark Trousdale, is to improve both digital engagement and automation in the financial services industry.</p> <p>As Trousdale noted, fee pressures are incredibly strong in the financial planning industry. Advisors are under more pressure to engage with their clients beyond just their portfolios.</p> <p>&ldquo;What a lot of wealth managers are telling me is that if we can show ...</p><p><a href=https://www.benzinga.com/personal-finance/financial-advisors/18/07/12046075/financial-advisers-need-to-be-more-engaging-and-t alt=Financial Advisers Need To Be More Engaging, And This Fintech Company Wants To Help>Full story available on Benzinga.com</a></p> Financial Advisors Fintech InvestCloud Personal Finance Interview Financial Advisors Fintech Personal Finance Interview Benzinga Thu, 19 Jul 2018 17:31:45 +0000 Spencer Israel 12046075 at https://www.benzinga.com EDM DJ 3LAU Launches A Blockchain Music Festival: 'Live Music Is A Collective Experience' https://www.benzinga.com/markets/cryptocurrency/18/07/12033278/edm-dj-3lau-launches-a-blockchain-music-festival-live-music-is <p>Of any music genre, one could argue that none has been influenced more by technology than electronic dance music.</p> <p>If this is true, then it makes sense that electronic DJs might be some of the first in the music business to embrace <a href="https://www.benzinga.com/markets/cryptocurrency/18/07/12003589/4-uses-for-blockchain-technology-you-hadnt-considered">blockchain technology</a>.</p> <p>Music producer and DJ Justin Blau, known professionally as 3LAU, is&nbsp;launching a blockchain-based platform for festival concert goers:&nbsp;<a href="https://omf.io/">Our Music Festival.</a></p> <p>The ecosystem of concertgoers looks to reward users with tokens after they attend concerts and refer friends. Benzinga spoke with Blau about the Our Music Festival platform. The interview has been edited for clarity and length.</p> <p><strong>Benzinga</strong>: Why is blockchain a valuable tool for live events?</p> <p><strong>3LAU</strong>: At the current moment, the different micro transfers between parties at festivals are not monetized or capturable. They are too expensive to capture on traditional payment experiences. What makes blockchain so fascinating is that you can capitalize on all these different micro transfers of value.</p> <p>Our goal was to find out what behavior ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/18/07/12033278/edm-dj-3lau-launches-a-blockchain-music-festival-live-music-is alt=EDM DJ 3LAU Launches A Blockchain Music Festival: &#039;Live Music Is A Collective Experience&#039;>Full story available on Benzinga.com</a></p> 3LAU Blockchain Cryptocurrency DJ Justin Blau GBTC Justin Blau Our Music Festival Travel Top Stories Exclusives Markets Interview General GBTC Cryptocurrency Travel Top Stories Exclusives Markets Interview General Benzinga Wed, 18 Jul 2018 13:52:13 +0000 Brett Hershman 12033278 at https://www.benzinga.com How Important Is The Yield Curve? https://www.benzinga.com/news/18/07/12025036/how-important-is-the-yield-curve <p>Bank earnings season is off to a mixed start, and bank investors haven&rsquo;t gotten the type of returns they had hoped for in a climate of rising interest rates. A major part of the problem: the flat yield curve. Here&rsquo;s a closer look at what the yield curve is and why it matters.</p> <h3>What Is The Yield Curve?</h3> <p>The yield curve is a plot of the yields of <a href="https://www.benzinga.com/markets/bonds">bonds </a>with equal credit quality but different maturity dates. For U.S. investors, the most commonly referenced yield curve is a plot of U.S. Treasury bonds with three-month, two-year, five-year and 30-year maturities.</p> <p>A typical yield curve includes much higher interest rates for maturities further into the future. In a ...</p><p><a href=https://www.benzinga.com/news/18/07/12025036/how-important-is-the-yield-curve alt=How Important Is The Yield Curve?>Full story available on Benzinga.com</a></p> Interest Rates News Shawn Cruz SPY TD Ameritrade XLF yield curve Education Treasuries Top Stories Exclusives Trading Ideas Interview General SPY US78462F1030 XLF US81369Y6059 News Education Treasuries Top Stories Exclusives Trading Ideas Interview General Benzinga Wed, 18 Jul 2018 11:48:04 +0000 Wayne Duggan 12025036 at https://www.benzinga.com Women Execs React To Cannabis Trends Report Highlighting The Rise Of Females In The Marijuana Industry https://www.benzinga.com/news/18/07/12032246/women-execs-react-to-cannabis-trends-report-highlighting-the-rise-of-females-in- <p>AxisWire, a Cannabis-focused PR tech-suite provider, and Green Market Report on Monday issued their <a href="https://www.axiswire.com/axiswire-2018-cannabis-trend-report/">2018 Cannabis Trend Report</a>, highlighting the most relevant tendencies in the marijuana industry.</p> <p>This year has seen major news items in the sector, ranging from the <a href="https://www.benzinga.com/markets/cryptocurrency/18/06/11929452/gw-pharmas-epidiolex-becomes-first-cannabis-based-fda-approved">FDA&rsquo;s approval</a> of <strong>GW Pharmaceuticals&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>)&rsquo;s Epidiolex, the first cannabis-based drug to be accepted by the agency; to Vermont&rsquo;s and Canada&rsquo;s legalization of recreational cannabis; and to the launch of adult-use sales in California.</p> <p>There also seemed to be some underlying movements going on in the cannabis industry, notably, the continued rise of women in cannabis.</p> <p><em>Related Link: <a href="http://www.benzinga.com/government/18/06/11911059/canada-legalizes-recreational-marijuana-nationwide-beginning-oct-17-expert">Canada Legalizes Recreational Marijuana Nationwide Beginning Oct. 17: Experts React</a></em></p> <h3>&lsquo;Wonder Women Of Weed&rsquo;</h3> <p>Roughly 27 percent of C-Suite level positions in the cannabis industry are occupied by women, according to Marijuana Business Daily; This beats the national average of 23 percent.</p> <p>It should be noted men are slowly taking over, as the figure for women in C-Suite level positions in cannabis stood at 36 percent in 2015. Nonetheless, women are putting out a fight, and finding common grounds to do so as a community.</p> <p>&ldquo;For women in cannabis, it has become a badge of honor to know that within their new burgeoning industry ready to take the globe by storm, they hold the largest percentage of ownership, management and control of any industry in the world for their gender. Therefore upon recognition of the possibility of losing that title, the women have begun to band together and work toward the goal of making cannabis the first industry in the world to achieve 50% female control,&rdquo; the report says.</p> <p>The report goes on to highlight the main women&rsquo;s organizations leading this battle, namely: <a href="http://www.benzinga.com/topic/women-grow">WomenGrow</a>, Ellementa, Industry Power Women (IPW), Supernova Women and <a href="https://www.benzinga.com/news/17/05/9475911/meet-one-woman-entrepreneur-whos-fighting-for-diversity-in-the-cannabis-industry">Women Abuv Ground</a>.</p> <p>Benzinga&#39;s own <a href="http://www.benzinga.com/topic/wonder-women-of-weed">Wonder Women of Weed</a>&nbsp;series was also highlighted: &ldquo;This series highlights the most accomplished
and exceptional women in the cannabis industry, and has been featured on Yahoo Finance, Entrepreneur, CNN Money and other mass media outlets.&quot;</p> <p>Cynthia Salarizadeh, CEO of AxisWire and Managing Partner at KCSA Strategic Communications, told Benzinga, &ldquo;The cannabis industry has taken the world by storm. It is an industry that will continue to expand and improve medicine, lifestyle and limitless alternative options for a sustainable future with industrial hemp. Historically, women are always directly connected to the advancement of agriculture. It is of no surprise that this industry would be where we have the most advantage. I believe women will reach 50% control in the next couple years.&rdquo;</p> <p><em>Cannabis investors can&#39;t afford to miss the <a href="http://bzcannabis.com/">Benzinga Cannabis Capital Conference</a>, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited&mdash;<a href="https://www.eventbrite.com/e/cannabis-capital-conference-2018-tickets-44926359952">get your tickets before they sell out</a>.</em></p> <h3>Industry Power Women React</h3> <p>Interested in what the leading women in the cannabis industry had ...</p><p><a href=https://www.benzinga.com/news/18/07/12032246/women-execs-react-to-cannabis-trends-report-highlighting-the-rise-of-females-in- alt=Women Execs React To Cannabis Trends Report Highlighting The Rise Of Females In The Marijuana Industry>Full story available on Benzinga.com</a></p> 2018 Cannabis Trend Report Academy AxisWire Canabis Cannabis cannabis news cannabis oil Cynthia Salarizadeh Cyo Ray Nystrom Ellementa Emily Paxhia Ganja Garden Socitey GetPlanty Green Market Report GWPH Hemp HMLSF Industry Power Women invest in marijuana IPW is marijuana Jacqueline Carly Karli Warner Kyra Reed legal marijuana legal weed Lindiskin Lindy Snider Lori Ferrara Maria & Jane marihuana marijuana marijuana dispensary marijuana laws marijuana legalization marijuana legalize marijuana news marijuana states med marijuana medical medical cannabis medical marijuana medicinal marijuana MJ Poseidon Asset Management pot Quim Rock Recreational Marijuana smoke weed smoking weed Supernova Women THC weed weed legalization weed news weed plant Women Abuv Ground Women In Cannabis Women in Weed WomenGrow Wonder Women of Weed Emerging Markets Movers & Shakers Top Stories Exclusives Markets Interview General GWPH MJ HMLSF Emerging Markets Movers & Shakers Top Stories Exclusives Markets Interview General Benzinga Tue, 17 Jul 2018 19:00:43 +0000 Javier Hasse 12032246 at https://www.benzinga.com 'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care https://www.benzinga.com/news/18/07/12025056/a-new-revolution-of-medicine-senseonics-brings-automation-to-diabetes-care <p>Automation and artificial intelligence are transforming everything from travel to finance to how garage doors are closed. The management of personal health is poised for similar disruption.</p> <p><strong>Fitbit Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fit#NYSE">FIT</a>) and <strong>Apple Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) have taken wearable-based health monitoring mainstream and set the stage to link sensors to drug delivery systems or therapy regimens.</p> <p>&ldquo;There&rsquo;s a lot that you can do with a small [device],&rdquo; Tim Goodnow, president and CEO of the diabetes-focused medtech company&nbsp;&nbsp;<strong>Senseonics Holdings Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sens#NYSE">SENS</a>), told Benzinga. &ldquo;Not only could it give direct feedback to the patient themselves or the caregiver, the doctors, in regard to any particular status in the moment, it&rsquo;s just a new revolution of medicine that we&rsquo;re heading into.&rdquo;</p> <h3>Autonomous Opportunities</h3> <p>Senseonics is at the vanguard of health automation. Its first step is commercializing the Eversense Glucose Monitoring System, which recently won&nbsp;FDA approval as the world&rsquo;s first implantable glucose sensor.</p> <p>&ldquo;We&rsquo;re actually observing a pretty significant transition in the managing of diabetes as a result of the advent of these technologies,&rdquo; Goodnow said of the wearable-implant combo.</p> <p>The smart transmitter is embedded in the arm to provide discreet vibratory alerts and send real-time glucose information to a connected mobile app via Bluetooth. The product ...</p><p><a href=https://www.benzinga.com/news/18/07/12025056/a-new-revolution-of-medicine-senseonics-brings-automation-to-diabetes-care alt=&#039;A New Revolution Of Medicine&#039;: Senseonics Brings Automation To Diabetes Care>Full story available on Benzinga.com</a></p> AAPL ABT Diabetes DXCM FIT IFTTT MDT SENS Tim Goodnow Health Care Top Stories Exclusives Tech Interview General FIT AAPL US0378331005 DXCM US2521311074 ABT US0028241000 MDT US5850551061 SENS Health Care Top Stories Exclusives Tech Interview General Benzinga Mon, 16 Jul 2018 19:09:23 +0000 Elizabeth Balboa 12025056 at https://www.benzinga.com Medical Marijuana Sales Decline Continues In Colorado As Recreational Weed Disrupts Market https://www.benzinga.com/news/18/07/12019422/medical-marijuana-sales-decline-continues-in-colorado-as-recreational-weed-disru <p><a href="https://www.benzinga.com/news/18/01/11047865/colorado-cannabis-sales-hit-1-49-billion-in-2017-taxes-up-to-247-million-medical">Medical marijuana sales </a>continue to slide in Colorado. For the first half of 2018, revenue fell 21 percent year-over-year to $165.8 million. Recreational sales&nbsp;rose 14 percent to $573 million.</p> <p>Total combined sales rose by 4 percent to reach $739 million, versus $710 million in the first half of 2017.</p> <p>In June alone, medical marijuana sales dropped by 30 percent year-over-year to $25.3 million, while recreational cannabis sales advanced 14 percent to $99.4 million.</p> <h3>Rec Market &#39;Disruptive&#39; To Medical Sales&nbsp;</h3> <p>&ldquo;Since April of 2017, we have observed negative year-over-year comps for medical marijuana sales,&rdquo; GreenWave Advisors founder and managing partner&nbsp;<strong>Matt Karnes&nbsp;</strong>told Benzinga. &ldquo;These results underscore our ...</p><p><a href=https://www.benzinga.com/news/18/07/12019422/medical-marijuana-sales-decline-continues-in-colorado-as-recreational-weed-disru alt=Medical Marijuana Sales Decline Continues In Colorado As Recreational Weed Disrupts Market>Full story available on Benzinga.com</a></p> Canabis Cannabis cannabis news Colorado Colorado Cannabis Colorado Marijuana Colorado Pot Colorado Weed Ganja GreenWave Advisors HMLSF legal marijuana legal weed marihuana marijuana marijuana dispensary marijuana laws marijuana legalization marijuana news marijuana states Matt Karnes med marijuana medical medical cannabis medical marijuana medicinal marijuana MJ News pot Recreational Marijuana THC weed weed legalization weed news Emerging Markets Markets Interview MJ HMLSF News Emerging Markets Markets Interview Benzinga Sat, 14 Jul 2018 18:41:25 +0000 Javier Hasse 12019422 at https://www.benzinga.com Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/trading-ideas/long-ideas/18/07/12019670/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry <p>This week,&nbsp;<strong>Tilray </strong>and <strong>Sproutly Canada</strong> went public, <strong>Sunniva </strong>announced plans to spin off its Canadian assets, <strong>Zynerba Pharmaceuticals </strong>posted positive data for its Phase 2 trial for ZYN002 in Fragile X syndrome, and <strong>Zogenix </strong>released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome.</p> <p>Michigan added 11 new ailments to its list of qualifying conditions for medical cannabis. These are arthritis, autism, chronic pain, colitis, inflammatory bowel disease, obsessive compulsive disorder, Parkinson&rsquo;s disease, rheumatoid arthritis, spinal cord injury, Tourette&rsquo;s syndrome and ulcerative colitis.</p> <p>&ldquo;Currently Michigan has a robust program of nearly 300,000 patients. With Autism now allowed and an additional 10 other indications,&nbsp;the Michigan cannabis program is expected to double, possibly triple in size,&rdquo; <strong>Medical Marijuana Inc.</strong> CEO Dr. Stuart Titus told Beniznga. &ldquo;Obviously, the&nbsp;&lsquo;test&rsquo;&nbsp;program of medical cannabis was a tremendous success&nbsp;&ndash;&nbsp;to the point where regulators felt that the expansion of the program served the best interests of the populace.&nbsp; It would be wonderful to see if the medical cannabis program will exist within a recreational state&nbsp;and possibly reach 1 million state residents.&rdquo;</p> <p>Looking back on the second quarter, Borchardt added: &ldquo;The Green Market Report Cannabis Company Index summary for the second quarter was released and it noted that overall cannabis stocks increased in value. Good news from the FDA and impressive IPOs in the sector led investors to feel that risk is lower than it was at the beginning of the year.&rdquo;</p> <h3><strong>Marijuana Indexes &amp; ETFs</strong></h3> <p>Despite the news, the <strong>United States Marijuana Index, </strong>which tracks 17 of the largest marijuana stocks in the U.S., lost 2.6 percent this week, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, tumbled 4.3 percent.</p> <p>Over the last five trading days, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) (TSE:HMMJ) slipped more than 2 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) shed almost 3 percent of its value. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) was up 1.5 percent.</p> <h3><strong>Stock Moves</strong></h3> <p>Here are some of the top marijuana stocks (market cap above $100 million) in U.S. exchanges and how the performed over the last five trading days:</p> <ul> <li><strong>22nd Century Group Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>): down 3.3 percent</li> <li><strong>Aphria Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/aphqf#OTC">APHQF</a>): up 0.8 percent</li> <li><strong>Aurora Cannabis Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acbff#OTC">ACBFF</a>): down 6.8 percent</li> <li><strong>CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): down 4.95 percent</li> <li><strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): down 4.4 percent</li> <li><strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): up 1.4 percent</li> <li><strong>Green Organic Dutchman Holdings Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgodf#OTC">TGODF</a>)<strong> </strong>down 0.3 percent</li> <li><strong>Green Thumb Industries Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) down 20.7 percent</li> <li><strong>GW Pharmaceuticals PLC- ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>): up 7.3 percent</li> <li><strong>Hiku Brands Company Ltd</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/djacf#OTC">DJACF</a>): up 13.6 percent</li> <li><strong>iAnthus Capital Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ithuf#OTC">ITHUF</a>): up 11.75 percent</li> <li><strong>Medical Marijuana Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mjna#OTC">MJNA</a>) down 1 percent</li> <li><strong>MedMen Enterprises Inc.</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) up 2 percent</li> <li><strong>MedReleaf Corp</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/medff#OTC">MEDFF</a>): down 3.4 percent</li> <li><strong>Scotts Miracle-Gro Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>): down 0.7 percent</li> <li><strong>THC Biomed Intl Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/thcbf#OTC">THCBF</a>): down 0.1 percent</li> <li><strong>Zynerba Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>): up 7.1 percent</li> </ul> <h3><strong>In Other News</strong></h3> <p>A consortium of cannabis-related media professionals are conducting a <strong>Cannabis Media Survey.</strong> You can answer following&nbsp;<a href="https://www.surveymonkey.com/r/CannabisMediaSurvey1">this link</a>.&nbsp;</p> <p>Canadian cannabis company&nbsp;Tilray Inc.<strong>&nbsp;</strong><a href="https://www.benzinga.com/news/18/07/11994858/canadian-cannabis-company-tilray-announces-ipo">filed for an initial public offering</a> on the Nasdaq, aiming to raise $135 million. The firm said it has applied to offer 9 million shares under the ticker &ldquo;TLRY&rdquo; at a price of $14 to $16 per share.</p> <p>&ldquo;The robust investment banking group involved with the IPO signals greater acceptance by the investing community of nationally licensed cannabis operations,&rdquo; said Medical Marijuana&#39;s Titus. &ldquo;Certainly, the progressive attitudes in Canada about cannabis are creating tremendous value for the licensed and legitimate enterprises. By contrast, in the US, we see no such investor interest in American companies, as they are only allowed to participate at the state level and remain federally &lsquo;questionable.&rsquo; Thus, America continues to prevent expansion and growth of the industry and will likely lose top talent to Canadian entrepreneurs as &lsquo;money talks.&rsquo;&rdquo;</p> <p>ACMPR Licensed Producer of cannabis <strong>Sproutly Canada, Inc.</strong> (CSE:SPR) commenced trading on the Canadian Securities Exchange.</p> <p>&ldquo;The level of investor excitement displayed on Sproutly&rsquo;s first day of trade as a public company was exceptional,&quot; said CEO Keith Dolo.&nbsp;&quot;There is a lot of enthusiasm right now, as we look to displace current extraction methods. The cannabis sector ...</p><p><a href=https://www.benzinga.com/trading-ideas/long-ideas/18/07/12019670/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ACBFF APHQF Cannabis CGC CNNRF CNTTF CRON Debra Borchardt DJACF Electrum Partners EMMBF Flowhub Front Range Biosciences Giadha Aguirre De Carcer Glen Senk Green Market Report GTBIF GWPH Harrison Phillips HMLSF invest in marijuana ITHUF Jodie Emery Jodie’s Joint Keith Dolo KSHB Larisa Bolivar Leslie Bocskor Long Ideas marijuana marijuana news marijuana stocks Mark Lakmaaker Marvin Washington MEDFF MJ MJ Freeway MJBizConm MJNA MMNFF New Frontier Data News North American Marijuana Index RVVQF Scott Boyes Sector ETFs SMG SNNVF Snoop Dogg SPLIF Sproutly SPY Stuart Titus TGODF THCBF Tilray URBN WDDMF Wes Moore WYNN XXII ZGNX ZYNE Emerging Markets Specialty ETFs Emerging Market ETFs Top Stories After-Hours Center Markets Movers Trading Ideas Interview ETFs General SPY US78462F1030 URBN US9170471026 WYNN US9831341071 SMG US8101861065 CGC MJNA US58463A1051 ZGNX US98978L1052 ITHUF XXII CNTTF GWPH SPLIF ZYNE THCBF ACBFF APHQF KSHB MJ EMMBF CNNRF DJACF MEDFF WDDMF HMLSF SNNVF CRON RVVQF TGODF MMNFF GTBIF Long Ideas Sector ETFs News Specialty ETFs Emerging Markets Emerging Market ETFs Top Stories After-Hours Center Markets Movers Trading Ideas Interview ETFs General Benzinga Fri, 13 Jul 2018 20:41:02 +0000 Javier Hasse 12019670 at https://www.benzinga.com Cannabis After Legalization: Vic Neufeld Shares Aphria's Plan For Growth https://www.benzinga.com/fintech/18/07/12018382/cannabis-after-legalization-vic-neufeld-shares-aphrias-plan-for-growth <p><em>Cannabis investors can&#39;t afford to miss the&nbsp;<a href="http://bzcannabis.com/">Benzinga Cannabis Capital Conference</a>, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited&mdash;<a href="https://www.eventbrite.com/e/cannabis-capital-conference-2018-tickets-44926359952">get your tickets before they sell out</a>.</em></p> <p><em>Ahead of the conference, we&rsquo;re interviewing the speakers who will deliver key insights on the cannabis space at the&nbsp;<a href="http://bzcannabis.com/">BZ Cannabis Capital Conference</a>. This installment features Vic Neufeld, the CEO of <a href="https://aphria.ca/">Aphria</a>.</em></p> <h2>What is the elevator pitch for your company?</h2> <p>Aphria&rsquo;s vision is to be the best performing cannabis company globally, providing investors with access to the most accretive cannabis opportunities around the world. The Company&rsquo;s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders&rsquo; multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.</p> <h2>How is your firm capitalizing on the opportunities in cannabis?</h2> <p>Aphria was founded in 2013 with a vision to produce high-quality medical cannabis in the most natural growing conditions. Our two co-founders, Cole Cacciavillani and John Cervini, saw a future in cannabis and decided to apply their 60 plus years of commercial agriculture experience to grow a few medical cannabis plants.</p> <p>Today, Aphria operates three state-of-the-art production facilities in Canada including the GMP-certified Aphria One, Aphria Diamond (early 2019), and our west-coast subsidiary Broken Coast Cannabis, craft growers of premium B.C.-bud. These facilities represent over 2.3M square feet of production and in 2019 will reach an annual production capability of 255,000 kg.</p> <p>We know how to grow, and we know how to grow to scale. We also know that tomorrow&rsquo;s cannabis products will revolutionize the way our patients and consumers integrate cannabis into their lives, which is why our laser-focus on innovation will continue to keep us one step ahead. Our Leamington operations include the Aphria 360-degree Innovation Centre and our recently announced Extraction Centre of Excellence.</p> <h2>What is the biggest challenge the company faces?</h2> <p>The biggest challenge is something that&rsquo;s facing the entire industry as we try to help the government achieve its objective of eliminating or significantly reducing the black market. I don&rsquo;t think it will ever be eliminated completely, but we&rsquo;re already going to be starting with one hand tied behind our back. Right out of the gate, several product categories that will not be permitted for sale in the adult-use market, including vapes, which currently represent a significant portion of the illegal market.&nbsp;</p> <p>We&rsquo;re also significantly restricted in how we can package ...</p><p><a href=https://www.benzinga.com/fintech/18/07/12018382/cannabis-after-legalization-vic-neufeld-shares-aphrias-plan-for-growth alt=Cannabis After Legalization: Vic Neufeld Shares Aphria&#039;s Plan For Growth>Full story available on Benzinga.com</a></p> Aphria Benzinga Cannabis Capital Conference Cannabis Fintech Vic Neufeld Interview Fintech Interview Benzinga Fri, 13 Jul 2018 17:02:42 +0000 Benzinga Events 12018382 at https://www.benzinga.com 4 Questions With Cannabics Pharmaceuticals CEO Eyal Barad https://www.benzinga.com/general/biotech/18/07/12001254/4-questions-with-cannabics-pharmaceuticals-ceo-eyal-barad <p><strong>Cannabics Pharmaceuticals Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnbx#OTC">CNBX</a>) is an Israel-based bio-pharma company focused on the development of &ldquo;precision medicine, personalized anti-cancer diagnostics and cannabis-based treatments.&rdquo;</p> <p>While there are currently no products sold under the Cannabics brand, the company does have a product licensed to <strong>Wana Brands </strong>that&#39;s sold in Colorado. The sustained release capsules are marketed in the jurisdiction of the regulated medical cannabis sector. Cannabics has been conducting clinical and preclinical trials, so Benzinga decided to reach out to CEO Eyal Barad to ask him about some of his team&rsquo;s findings and conclusions.</p> <p>&ldquo;We believe we&#39;re on a very important mission here, as things are changing quite rapidly [with] regulation&nbsp;[of]&nbsp;cannabinoids,&rdquo; Barad said.</p> <p><strong><em>Benzinga: Tell us about an exciting thing you&rsquo;ve done.</em></strong></p> <p><strong>Barad:</strong> Four years ago, we came out with a slow release capsule that we put into preclinical trials at a hospital here in Israel to help with palliative advanced cancer patients suffering from cancer-related anorexia/cachexia (CACS). Our markers were weight gain, appetite and overall well-being in quality of life. We also included a marker for anti-cancer activity.</p> <p>In addition, we did a study with one of the major universities here in Israel and <a href="https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-receives-positive-results-from-preclinical-study-on-antitumor-effects-of-cannabinoids-678270833.html">results showed</a> that various dosages of cannabinoids affect various cancer cells differently. We also found that the optimal combination of those cannabinoids can cause apoptosis on cancer cells &mdash; the cancer cells die ...</p><p><a href=https://www.benzinga.com/general/biotech/18/07/12001254/4-questions-with-cannabics-pharmaceuticals-ceo-eyal-barad alt=4 Questions With Cannabics Pharmaceuticals CEO Eyal Barad>Full story available on Benzinga.com</a></p> Biotech Cannabics Pharmaceuticals Cannabis cannabis news cannabis oil CNBX Eyal Barad Ganja GWPH Hemp invest in marijuana is marijuana legal marijuana legal weed marijuana marijuana stocks medical marijuana THC Wana Brands Emerging Markets Top Stories Exclusives Markets Interview General GWPH CNBX Biotech Emerging Markets Top Stories Exclusives Markets Interview General Benzinga Fri, 13 Jul 2018 16:40:16 +0000 Javier Hasse 12001254 at https://www.benzinga.com Sail Cannabis CEO Prad Sekar Is Bringing Medical Cannabis Into Mainstream Health Care For Better Patient Care https://www.benzinga.com/fintech/18/07/12017781/sail-cannabis-ceo-prad-sekar-is-bringing-medical-cannabis-into-mainstream-hea <p><em>Cannabis investors can&#39;t afford to miss the <a href="http://bzcannabis.com/">Benzinga Cannabis Capital Conference</a>, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited&mdash;<a href="https://www.eventbrite.com/e/cannabis-capital-conference-2018-tickets-44926359952">get your tickets before they sell out</a>.</em></p> <p><em>Ahead of the conference, we&rsquo;re interviewing the speakers who will deliver key insights on the cannabis space at the&nbsp;<a href="http://bzcannabis.com/">BZ Cannabis Capital Conference</a>. This installment features Prad Sekar with <a href="https://sailcannabis.co/home">Sail Cannabis</a>.</em></p> <h2>Quickly give us your background, why are you passionate about cannabis?</h2> <p>My background is rooted in both tech and healthcare. In the past I&rsquo;ve worked alongside licensed producers to provide improved access to patients by creating tools for physicians.</p> <p>Currently, there is a problem with many medical cannabis frameworks across the globe. Patients have limited access to an alternative medicine due to a cannabis knowledge gap experienced by physicians. Many health professionals are hesitant to prescribe cannabis for a number of reasons; however their medical school education didn&rsquo;t include any literature on this new medicine. My passion, specifically with Sail, is to close this cannabis knowledge gap, helping doctors dose and prescribe medical cannabis, ultimately helping patients access a medicine that can treat a long list of conditions, while being much safer and less addictive than treatment with opioids.</p> <h2>What is the most exciting opportunity in the cannabis space right now?</h2> <p>The cannabis industry is constantly evolving. New products, new ideas, new companies and voices are constantly inserting themselves into the industry. It&rsquo;s an exciting time for everyone.</p> <p>I think it&rsquo;s incredibly exciting to see new clinical research being published in medical journals supporting the efficacy of cannabis. The more literature published on the topic ...</p><p><a href=https://www.benzinga.com/fintech/18/07/12017781/sail-cannabis-ceo-prad-sekar-is-bringing-medical-cannabis-into-mainstream-hea alt=Sail Cannabis CEO Prad Sekar Is Bringing Medical Cannabis Into Mainstream Health Care For Better Patient Care>Full story available on Benzinga.com</a></p> Benzinga Cannabis Capital Conference Cannabis Fintech Opioids Prad Sekar Sail Cannabis Health Care Interview General Fintech Health Care Interview General Benzinga Fri, 13 Jul 2018 14:42:25 +0000 Benzinga Events 12017781 at https://www.benzinga.com How Lossless Cannabis Activation Allows Users To Access All Of A Strain's Properties https://www.benzinga.com/general/biotech/18/07/12000462/how-lossless-cannabis-activation-allows-users-to-access-all-of-a-stra <p>Earlier this year, Benzinga published <a href="https://www.benzinga.com/general/biotech/18/03/11035855/smoking-is-just-one-way-to-use-marijuana-an-introduction-to-vaporizer">an article</a> looking into ways of consuming cannabis that didn&#39;t involve smoking. such as vaporization, edibles, oils, tinctures and dabs.</p> <p>Even more options are emerging. The cannabis industry has evolved beyond simply eliminating the risks associated with smoking or solving the issue of inconsistent dosing in edibles to address more complex problems like the degradation of certain molecules during extraction, activation or infusion processes.</p> <p>How can patients obtain the complete spectrum of medical properties the cannabis plant has to offer? How can the cannabinoids in cannabis be activated without degrading original strain profiles?</p> <p>The questions above are behind <strong>Harvest Direct Enterprises</strong>, a company focused on the investigation of lossless activation and infusion. In less than two years, the company&rsquo;s co-founding brothers, Zeyead and Ahmed Gharib, have developed a device that solves the activation problem: the Lossless Activation Chamber Y, or LACY.</p> <h3>Lossless Activation</h3> <p>Unlike its peers, the LACY can fully activate cannabis without altering its terpene profile, according to HDE. What this means is that, if a cannabis user is ...</p><p><a href=https://www.benzinga.com/general/biotech/18/07/12000462/how-lossless-cannabis-activation-allows-users-to-access-all-of-a-stra alt=How Lossless Cannabis Activation Allows Users To Access All Of A Strain&#039;s Properties>Full story available on Benzinga.com</a></p> 710 Ahmed Gharib Biotech Cannabis cannabis news cannabis oil cannabis tincture dabbing Dabs edibles Ganja Harvest Direct Enterprises HDE Hempfest HMLSF invest in marijuana is marijuana LACY legal marijuana legal weed Lossless Activation Lossless Activation Chamber Y marihuana marijuana marijuana legalize marijuana news med marijuana medical medical cannabis medical marijuana medicinal marijuana MJ MJBizCon Oaksterdam University pot smoke weed smoking weed THC vaporization vaporizers weed weed news weed plant Zeyead Gharib Education Emerging Markets Top Stories Markets Tech Interview General MJ HMLSF Biotech Education Emerging Markets Top Stories Markets Tech Interview General Benzinga Wed, 11 Jul 2018 20:37:42 +0000 Javier Hasse 12000462 at https://www.benzinga.com PreMarket Prep for July 9: Monday's 'Buy The Dip' Market; David Breuhan On Trade Tariffs https://www.benzinga.com/general/biotech/18/07/11992103/premarket-prep-for-july-9-mondays-buy-the-dip-market-david-breuhan-on <p>On Monday&#39;s&nbsp;<a href="http://premarket.benzinga.com">PreMarket Prep</a>, Joel and Dennis were joined by David Breuhan, Vice President of Schwartz &amp; Co. Investment Advisors, who pointed to how we can learn from history to see that trade tariffs will hurt the market.&nbsp;</p> <p>Watch the show on<a href="https://www.youtube.com/watch?v=dNy6DtvGJI4">&nbsp;</a>Youtube below, or listen to the <a href="https://soundcloud.com/bztv/premarket-prep-for-july-9-mondays-buy-the-dip-market-david-breuhan-on-trade">podcast here</a>. Our interview with David begins at the 17:30 mark of the video and 15:30 in the podcast.</p> <p><iframe width="560" height="315" src="https://www.youtube.com/embed/yGHqsir5K8Q" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe></p> <h3>Discussion topics on today&rsquo;s show:</h3> <ul> <li>Biotech&#39;s strength leading the market on Friday</li> <li>Upgrades to <strong>FireEye Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/feye#NASDAQ">FEYE</a>) and <strong>Baidu Inc (ADR)</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>)</li> <li>How to approach trading&nbsp;<strong>Celgene Corporation</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celg#NASDAQ">CELG</a>)</li> </ul> <h3>Featured Guests:</h3> <p><strong>David Breuhan, Vice President of Schwartz &amp; Co. Investment Advisors; Author of &ldquo;Spread ...</strong></p><p><a href=https://www.benzinga.com/general/biotech/18/07/11992103/premarket-prep-for-july-9-mondays-buy-the-dip-market-david-breuhan-on alt=PreMarket Prep for July 9: Monday&#039;s &#039;Buy The Dip&#039; Market; David Breuhan On Trade Tariffs>Full story available on Benzinga.com</a></p> BIDU Biotech CELG FEYE Long Ideas News Premarket PreMarket Prep tariffs Trade trading Education Short Ideas Small Cap Analysis Futures Technicals Options Pre-Market Outlook Markets Movers Trading Ideas Interview General BIDU US0567521085 CELG US1510201049 FEYE Long Ideas News Biotech Short Ideas Education Small Cap Analysis Futures Technicals Options Pre-Market Outlook Markets Movers Trading Ideas Interview General Benzinga Mon, 09 Jul 2018 14:14:28 +0000 Spencer Israel 11992103 at https://www.benzinga.com Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/general/biotech/18/07/11988075/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-wee <p>A shortened week brought less cannabis news than usual, providing the people in the industry with a chance to exhale&nbsp;and look back at the convoluted weeks leading up to the Fourth of July holiday.&nbsp;</p> <p>We did witness some relevant action.</p> <p><strong>Zynerba Pharmaceuticals Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>) reported that its Phase 1 study of ZYN001 failed;<a href="https://www.benzinga.com/general/biotech/18/07/11980463/zynerba-redirects-resources-after-zyn001-study-fails-to-meet-top-line"> the company said it will now focus on the ZYN002 candidate</a>, Green Market Report CEO Debra Borchardt told Benzinga.&nbsp;</p> <p>&quot;The stock initially took a beating on the day this was announced, but then losses were trimmed,&quot; Borchardt said.&nbsp;</p> <p>She referenced <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/07/11982955/hc-wainwright-unfazed-by-zynerba-ending-zyn001-drug-was">H.C. Wainwright analyst Oren Livnat&#39;s Thursday note</a>; the analyst reiterated a Buy rating on Zynerba and said ZYN001 was not included in the firm&#39;s bullish thesis for the stock.&nbsp;</p> <p>&quot;Still, this same analyst only belives that ZYN002 has a 35-percent chance of being successful,&quot; Borchardt said. &quot;ZYN002 had one disappointing study last year and that sent the stock down back then. It seems investors really believe in Zynerba and I feel they believe it will eventually begin to act like <strong>GW Pharmaceuticals PLC- ADR</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>).&quot;</p> <h3>Marijuana Indexes On The Rise</h3> <p>Despite the scarcity of news, the <strong>United States Marijuana Index, </strong>which tracks 17 of the largest marijuana stocks in the U.S., gained about 4.3 percent in the four days of this week, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, surged roughly 2.2 percent.</p> <p>Over the last five trading days, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) (TSE: HMMJ) rose 2 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) added 1.4 percent to its value. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) was up 1.4 percent.</p> <h3>Stock Moves</h3> <p>Here&#39;s a look at some of the top marijuana stocks in U.S. exchanges and their performance&nbsp;over the last five trading days:</p> <ul> <li><strong>22nd Century Group Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>): up 15.65 percent.</li> <li><strong>Aphria Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/aphqf#OTC">APHQF</a>): down 0.4 percent.</li> <li><strong>Aurora Cannabis Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acbff#OTC">ACBFF</a>): up 1.1 percent.</li> <li><strong>Cannabis Sativa Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cbds#OTC">CBDS</a>): up 9.1 percent.</li> <li><strong>CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): down 0.6 percent.</li> <li><strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): up 2.5 percent.</li> <li><strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): up 6.75 percent.</li> <li><strong>GW Pharma</strong>: up 1.2 percent.</li> <li><strong>Hiku Brands Company Ltd</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/djacf#OTC">DJACF</a>): up 3.7 percent.</li> <li><strong>India Globalization Capital, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/igc#NYSE">IGC</a>): up 0.6 percent.</li> <li><strong>iAnthus Capital Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ithuf#OTC">ITHUF</a>): down 10.5 percent.</li> <li><strong>MassRoots Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/msrt#OTC">MSRT</a>): down 14 percent.</li> <li><strong>MedReleaf Corp</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/medff#OTC">MEDFF</a>): up 12.3 percent.</li> <li><strong>Scotts Miracle-Gro Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>): up 3.1 percent.</li> <li><strong>THC Biomed Intl Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/thcbf#OTC">THCBF</a>): up 1 percent.</li> <li><strong>Zynerba Pharma:</strong>&nbsp;down 16.1 percent.</li> </ul> <h3>In Other News</h3> <p>A consortium of cannabis-related media professionals are conducting a <strong>Cannabis Media Survey.</strong> You can respond by following&nbsp;<a href="https://www.surveymonkey.com/r/CannabisMediaSurvey1" style="color:blue; text-decoration:underline">this link</a>. When finished, you can email your name and email to&nbsp;<a href="mailto:info@greenmarketreport.com" style="color:blue; text-decoration:underline">info@greenmarketreport.com</a>&nbsp;and enter a raffle for&nbsp;two <strong>Magical Butter </strong>machines.</p> <p><strong>Canopy Growth</strong> <strong>Corp.</strong> announced the debut of its new Latin American wholly-owned subsidiary, Canopy LATAM Corp., and the acquisition&nbsp;through that&nbsp;subsidiary&nbsp;of Spectrum Cannabis Colombia S.A.S, a Colombian licensed medical cannabis producer.</p> <p>&ldquo;Today is a historic day for Canopy Growth and a victory for patients across Latin America as we take a leap forward in the future of medical ...</p><p><a href=https://www.benzinga.com/general/biotech/18/07/11988075/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-wee alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ACBFF Alan Brochstein APHQF Aras Azadian ArcView Market Research BDS Analytics Biotech Brett Roper Canada Cannabis Canada Marijuana Cannabis Cannabis ETF cannabis news Cannabis Stock Index cannabis stocks Canopy LATAM CBDS CBWTF CGC CNTTF Colombia Cannabis Colombia Marijuana CRON Cynthia Salarizadeh Debra Borchardt DJACF Dr. Kerklaan Flow Kana Giadha Aguirre De Carcer Gotham Green Partners Green Market Report GWPH Hadley Ford Harrison Phillips HeadCount HelloMD Hempfest HMLSF IGC invest in marijuana ITHUF Javier Hasse Keef Brands Larisa Bolivar Long Ideas Marc Brownstein marijuana Marijuana ETF Marijuana Index Marijuana Money marijuana news marijuana stocks Mark Lakmaaker Marvin Washington Massachusetts Cannabis Massachusetts Marijuana MEDFF Michael Caridi MJ MSRT New Frontier Data News Nick Kovacevich North American Marijuana Index Pamela Hadfield Poseidon Asset Management Pot Stocks PRMCF Roger McNamee Salveo Capital Scott Boyes SMG SNOVF SPY THCBF The Disco Biscuits Tim Seymour TOK Tree of Knowledge United States Marijuana Index Vermont Cannabis Vermont Marijuana XXII ZYNE Emerging Markets Specialty ETFs Politics Markets Movers Trading Ideas Interview ETFs General IGC US45408X1000 SPY US78462F1030 SMG US8101861065 CGC ITHUF XXII CNTTF GWPH CBDS SNOVF MSRT ZYNE THCBF ACBFF APHQF MJ PRMCF DJACF CBWTF MEDFF HMLSF CRON Long Ideas News Biotech Specialty ETFs Emerging Markets Politics Markets Movers Trading Ideas Interview ETFs General Benzinga Fri, 06 Jul 2018 21:37:40 +0000 Javier Hasse 11988075 at https://www.benzinga.com PreMarket Prep Recap For July 6: Digesting Biogen's News With Adam Feuerstein; A Sector Breakdown With Dan Russo https://www.benzinga.com/general/biotech/18/07/11986618/premarket-prep-recap-for-july-6-digesting-biogens-news-with-adam-feue <p>On Thursday&#39;s&nbsp;<a href="http://premarket.benzinga.com">PreMarket Prep</a>, Joel and Dennis were joined by STAT News Senior Writer Adam Feuerstein, who broke down the surprising Alzheimer&#39;s drug news from <strong>Biogen Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>), and Chaikin Analytics Chief Market Strategist Dan Russo, who highlighted several sectors he&#39;s bullish on right now.&nbsp;</p> <p>Watch the show on<a href="https://www.youtube.com/watch?v=dNy6DtvGJI4">&nbsp;</a>Youtube below, or listen to the <a href="https://soundcloud.com/bztv/premarket-prep-for-july-6-adam-feuerstein-breaks-down-biib-dan-russos-sector-breakdown?in=bztv/sets/2018-shows">podcast here</a>.</p> <p><iframe width="560" height="315" src="https://www.youtube.com/embed/xzq0tDsPhGg" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe></p> <h3>Discussion topics on today&rsquo;s show:</h3> <ul> <li>What the Biogen headline really means, and whether the rest of the sector could get propped up on this news</li> <li>The trading action around the Jobs Number</li> <li>Why the financials are unattractive right now</li> </ul> <h3>Featured Guests:</h3> <p><strong><a href="http://twitter.com/adamfeuerstein">Adam Feuerstein, Senior Writer at STAT News</a> <a href="https://soundcloud.com/bztv/premarket-prep-for-july-6-adam-feuerstein-breaks-down-biib-dan-russos-sector-breakdown?in=bztv/sets/2018-shows#t=8:50">(08:50)</a></strong><br /> Adam Feuerstein is STAT&rsquo;s ...</p><p><a href=https://www.benzinga.com/general/biotech/18/07/11986618/premarket-prep-recap-for-july-6-digesting-biogens-news-with-adam-feue alt=PreMarket Prep Recap For July 6: Digesting Biogen&#039;s News With Adam Feuerstein; A Sector Breakdown With Dan Russo>Full story available on Benzinga.com</a></p> BIIB Biotech Long Ideas News PreMarket Prep Education Short Ideas Futures Technicals Previews Options Econ #s Economics Pre-Market Outlook Markets Movers Trading Ideas Interview General BIIB US09062X1037 Long Ideas News Biotech Short Ideas Education Futures Technicals Previews Options Econ #s Economics Pre-Market Outlook Markets Movers Trading Ideas Interview General Benzinga Fri, 06 Jul 2018 15:11:37 +0000 Spencer Israel 11986618 at https://www.benzinga.com